China Digest: Teligene, AnchorDx in funding news

Teligene has raised over 600 million yuan ($93 million) in its pre-IPO round from GTJA Investment Group, while AnchorDx has raked in $40 million in its Series C round jointly led by OrbiMed and Wuxi Huiying Investment.

Teligene snags $93m in pre-IPO round 

Small-molecular drug discovery firm Teligene Ltd has pocketed over 600 million yuan ($93 million) in its pre-IPO round from existing investor GTJA Investment Group, a Shenzhen-based healthcare fund with more than 20 billion yuan ($3 billion) in asset management.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter